<DOC>
	<DOCNO>NCT02566759</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics ( PK ) single multiple rise dos TAK-831 healthy participant .</brief_summary>
	<brief_title>A TAK-831-1001 , Single Multiple Rising Dose Study Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-831 . TAK-831 test treat people schizophrenia cerebellar ataxia . This study look PK , safety tolerability TAK-831 healthy participant . The study enroll approximately 96 participant . The study include 3 part : Part 1 ( single-rising dose [ SRD ] ) , Part 2 ( SRD/multiple-rising dose [ MRD ] ) , Part 3 ( MRD ) . Participants randomly assign ( chance , like flip coin ) receive either active drug TAK-831 placebo remain undisclosed patient study doctor study ( unless urgent medical need ) : - Part 1 , Cohort 1 : single dose TAK-831 100 mg - Part 1 , Cohort 2 : single dose TAK-831 250 mg - Part 1 , Cohort 3 : single dose TAK-831 500 mg - Part 1 , Cohort 4 : single dose TAK-831 750 mg - Doses cohort 5 6 determined basis tolerability dose previous cohort . Dosing TAK-831 progress study part 2 3 , review available safety , tolerability , PK data collect Cohorts 1 2 Study Part 1 This single center trial conduct United Kingdom . The overall time participate study approximately 58 day . Participants admit clinic 20 day , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<criteria>1 . Should capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Healthy male female age 18 55 year Weighing least 45 kilogram ( kg ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) . 4 . Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 5 . Female participant childbearing potential , defined participant surgically sterilize ( hysterectomy , bilateral oophorectomy tubal ligation ) post menopausal ( define continuous amenorrhea least 2 year folliclestimulating hormone ( FSH ) great [ &gt; ] 40 international unit per liter [ IU/L ] ) . 1 . Received investigational compound within 3 month prior randomization . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 3 . Has uncontrolled , clinically significant neurological ( include seizure disorder ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder , abnormality . 4 . Has know hypersensitivity component formulation TAK831 . 5 . Female participant childbearing potential . 6 . Has positive urine drug result drug abuse ( define illicit drug use ) Screening Checkin ( Day 2 ) . 7 . Has take exclude medication , supplement , food product time period list excluded medication dietary product . 8 . Female participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 9 . Male participant intend donate sperm course study 12 week last dose study medication . 10 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma , hypoxemia , hypertension , seizure , allergic skin rash . 11 . Has QT interval Fridericia 's correction method ( QTcF ) &gt; 450 millisecond ( msec ) ( male ) &gt; 470 msec ( female ) PR outside range 120 220 msec , confirm one repeat testing , screen visit checkin ( Day 2 ) . 12 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention . 13 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 14 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen Screening . 15 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 2 ) . Cotinine test positive Screening Checkin ( Day 2 ) . 16 . Has poor peripheral venous access . 17 . Has donate lose 450 milliliter ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Day 1 . 18 . Has Screening Checkin ( Day 2 ) abnormal ( clinically significant ) ECG . Entry subject abnormal ( clinically significant ) ECG must approve , document signature principal investigator designee . 19 . Has supine blood pressure outside range &lt; 90 &gt; 140 mm Hg systolic le ( &lt; ) 50 &gt; 90 mm Hg diastolic , confirm repeat test within maximum 30 minute , Screening Visit Checkin ( Day 2 ) . 20 . Has rest heart rate outside range &lt; 40 &gt; 100 bpm confirm repeat test within maximum 30 minute , Screening Visit Checkin ( Day 2 ) . 21 . Has abnormal Screening Day 2 laboratory value suggest clinically significant underlying disease subject follow lab abnormality : Alanine transaminase ( ALT ) and/or AST ( aspartate aminotransferase ) &gt; 1.5 upper limit normal . 22 . Has risk suicide accord Investigator 's clinical judgment ( eg , per The Columbia Suicide Severity Rating Scale [ CSSRS ] ) , score `` yes '' item 4 item 5 Suicidal Ideation section CSSRS , ideation occur past 6 month , `` yes '' item Suicidal Behavior section , except `` NonSuicidal SelfInjurious Behavior '' , behaviour occur past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>